European shares closed lower on Thursday, with defence and industrial stocks leading losses, after data showed U.S. inflation ...
European shares ended slightly lower, driven by losses in defence and industrial sectors, amid rising U.S. inflation and ...
The predicted rise in forecourt prices comes as the amount paid by drivers for petrol has fallen by 15.5p since the start of ...
Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity ...
FOR too long, governments have failed British industry and British workers. Administrations of all colours bought into the ...
With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...
The market for B7-H3 inhibitors is expected to grow significantly in the coming years. This is due to the rising investment from leading pharma companies such as GSK, Merck, and others, the increasing ...
The first phase 3 trials are due to start in the first half of next year, using devices manufactured at GSK’s facility in Evreux, France. “If successful, this could lead to regulatory ...
The following is a summary of “Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually ...
The proposed offer from Clayton, Dubilier & Rice (CD&R) would mean the sale of a 50% stake in Opella, which makes ...
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
GSK’s Zejula boasts a broad U.S. approval as ... This month, the drug just won reimbursement in France for that first-line maintenance use, the company spokesperson said.
The Bank of England risks inflicting unnecessary damage to the economy by keeping interest rates too high for too long, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback